​

Viridian Therapeutics Ownership | Who Owns Viridian Therapeutics?

OverviewForecastRevenueFinancialsChart

Viridian Therapeutics Ownership Summary

Viridian Therapeutics is owned by 133.80% institutional investors, 0.13% insiders. Fmr is the largest institutional shareholder, holding 16.25% of VRDN shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 3.40% of its assets in Viridian Therapeutics shares.

VRDN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockViridian Therapeutics133.80%0.13%-33.93%
SectorHealthcare Stocks 244.37%12.11%-156.48%
IndustryBiotech Stocks 379.01%11.75%-290.76%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr16.60M16.25%$305.03M
Blackrock funding, inc. /de8.55M8.37%$157.09M
Blackrock4.77M7.81%$62.10M
Vanguard group5.61M6.86%$174.65M
Bellevue group6.73M6.59%$123.67M
Paradigm biocapital advisors lp6.72M6.58%$123.52M
Kynam capital management, lp6.45M6.31%$118.56M
State street6.12M5.99%$112.52M
Price t rowe associates inc /md/5.75M5.62%$105.60M
Fairmount funds management5.09M4.98%$93.52M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp6.45M6.55%$118.56M
Fairmount funds management5.09M6.18%$93.52M
Commodore capital lp3.20M3.37%$69.06M
First turn management1.67M3.28%$30.68M
Bellevue group6.73M2.60%$123.67M
Parkman healthcare partners1.38M2.59%$25.31M
Yiheng capital management400.46K2.53%$7.36M
Ghost tree capital587.71K2.39%$7.65M
Paradigm biocapital advisors lp6.72M2.31%$123.52M
Novo2.13M2.28%$39.22M

Top Buyers

HolderShares% AssetsChange
Kynam capital management, lp6.45M6.55%4.11M
Paradigm biocapital advisors lp6.72M2.31%3.57M
Price t rowe associates inc /md/5.75M0.01%2.54M
Deep track capital, lp3.59M0.96%2.20M
Caligan partners lp2.19M1.90%2.19M

Top Sellers

HolderShares% AssetsChange
Citadel advisors41.30K0.00%-2.28M
Maverick capital---2.21M
Ecor1 capital---1.96M
Commodore capital lp3.20M3.37%-1.68M
Balyasny asset management1.28M0.03%-1.04M

New Positions

HolderShares% AssetsChangeValue
Caligan partners lp2.19M1.90%2.19M$40.30M
Sixth street partners management company815.03K0.00%815.03K$14.97M
Boothbay fund management541.06K0.13%541.06K$9.94M
Emerald advisers537.33K0.23%537.33K$9.87M
Ikarian capital425.00K0.84%425.00K$7.81M

Sold Out

HolderChange
True wealth design-4.00
Massmutual trust co fsb/adv-8.00
Nelson, van denburg & campbell wealth management group-8.00
Principal securities-9.00
Stone house investment management-9.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2026224-2.61%136,760,03921.70%1331.11%1417.63%54-16.92%
Mar 31, 2026229-1.72%112,362,8144.21%1320.76%130-18.75%6541.30%
Dec 31, 2025145-17.14%44,766,785-51.97%540.42%10146.38%28-57.58%
Sep 30, 2025172-1.15%92,157,310-2.54%1120.84%68-21.84%651.56%
Jun 30, 2025174-1.69%94,556,3498.58%1151.01%87-6.45%6416.36%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF3.85M3.40%8.84K
Vanguard Total Stock Mkt Idx Inv3.34M3.02%-10.49K
Vanguard Morn Total Stk Mkt Idx Investor3.34M3.02%-10.49K
Vanguard MStar Total Stk Mkt Idx Invest3.36M2.96%17.68K
Vanguard US Total Market Shares ETF2.24M2.75%324.50K
iShares Russell 2000 ETF2.30M2.03%-40.80K
Fidelity Advisor Biotechnology I1.78M1.61%-
Fidelity Select Health Care1.50M1.36%-
T. Rowe Price Health Sciences1.45M1.31%1.14M
Strategic Advisers Fidelity US TtlStk1.39M1.26%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 19, 2026Tousignant Jennifer Chief Legal OfficerSell$245.00K
May 11, 2026Fairmount Funds Management LLC Buy$20.00M
Dec 31, 2025Tousignant Jennifer Chief Legal OfficerSell$70.80K
Oct 23, 2025Fairmount Funds Management LLC Buy$10.00M
Sep 27, 2024Beetham Thomas W. Chief Operating OfficerBuy$117.05K

Insider Transactions Trends

DateBuySell
2026 Q3-1
2026 Q21-
2026 Q1--
2025 Q411
2025 Q3--

VRDN Ownership FAQ

Who Owns Viridian Therapeutics?

Viridian Therapeutics shareholders are primarily institutional investors at 133.80%, followed by 0.13% insiders and -33.93% retail investors. The average institutional ownership in Viridian Therapeutics's industry, Biotech Stocks , is 379.01%, which Viridian Therapeutics falls below.

Who owns the most shares of Viridian Therapeutics?

Viridian Therapeutics’s largest shareholders are Fmr (16.6M shares, 16.25%), Blackrock funding, inc. /de (8.55M shares, 8.37%), and Blackrock (4.77M shares, 7.81%). Together, they hold 32.42% of Viridian Therapeutics’s total shares outstanding.

Does Blackrock own Viridian Therapeutics?

Yes, BlackRock owns 7.81% of Viridian Therapeutics, totaling 4.77M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.1M$. In the last quarter, BlackRock increased its holdings by 960.99K shares, a 25.21% change.

Who is Viridian Therapeutics’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Viridian Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.55% of its assets in 6.45M Viridian Therapeutics shares, valued at 118.56M$.

Who is the top mutual fund holder of Viridian Therapeutics shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Viridian Therapeutics shares, with 3.40% of its total shares outstanding invested in 3.85M Viridian Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools